LOIM
CRSP icon

Liberty One Investment Management’s CRISPR Therapeutics CRSP Stock Holding History

Liberty One Investment Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,557
Closed -$120K – 156
2024
Q3 		$120K Sell
2,557
-148
-5% -$7.51K 0.01% 148
2024
Q2 		$146K Buy
2,705
+336
+14% +$19.4K 0.02% 150
2024
Q1 		$161K Sell
2,369
-1,047
-31% -$75K 0.02% 141
2023
Q4 		$214K Buy
3,416
+40
+1% +$2.21K 0.03% 121
2023
Q3 		$153K Sell
3,376
-272
-7% -$14K 0.02% 119
2023
Q2 		$205K Sell
3,648
-226
-6% -$12.8K 0.03% 118
2023
Q1 		$175K Sell
3,874
-38
-1% -$1.85K 0.02% 121
2022
Q4 		$159K Hold
3,912
– – 0.02% 121
2022
Q3 		$256K Buy
3,912
+2,237
+134% +$162K 0.04% 112
2022
Q2 		$271K Sell
1,675
-2,346
-58% -$138K 0.05% 117
2022
Q1 		$252K Buy
4,021
+1,407
+54% +$88.3K 0.04% 117
2021
Q4 		$198K Buy
2,614
+1,010
+63% +$88.2K 0.03% 127
2021
Q3 		$180K Sell
1,604
-71
-4% -$8.92K 0.03% 130
2021
Q2 		$271K Buy
1,675
+378
+29% +$46K 0.05% 124
2021
Q1 		$158K Buy
1,297
+339
+35% +$51.2K 0.03% 132
2020
Q4 		$147K Sell
958
-14
-1% -$1.66K 0.03% 112
2020
Q3 		$81K Buy
972
+358
+58% +$31.8K 0.02% 123
2020
Q2 		$45K Buy
+614
New +$35.9K 0.01% 116

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Liberty One Investment Management's CRSP Position: Q4 2024 in Review

Liberty One Investment Management sold out of CRISPR Therapeutics (CRSP) in Q4 2024, closing a stake of 2,557 shares — an estimated $120K sold.

Liberty One Investment Management first reported a position in CRSP in Q2 2020 and held it in 18 quarters. The position peaked at $271K in Q2 2022. 404 funds tracked by Wall St. Rank hold CRSP as of Q4 2024.

  • Liberty One Investment Management reported no remaining CRISPR Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Liberty One Investment Management sold 2,557 CRISPR Therapeutics shares in Q4 2024, an estimated $120K.
  • Liberty One Investment Management first reported a position in CRISPR Therapeutics in Q2 2020 and held it in 18 quarters.
  • Liberty One Investment Management's CRISPR Therapeutics position peaked at $271K in Q2 2022.
  • 404 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2024.

Based on Liberty One Investment Management's 13F filing for Q4 2024, filed 16 Jan 2025.